Tagged Articles

dipeptidyl peptidase-4 inhibitor 5 articles

Diabetes drug Janumet safety label updated

The Food and Drug Administration (FDA) has updated the safety label for the type 2 diabetes drug Janumet XR to inform users that incompletely dissolved tablets may be eliminated in the feces. If this occurs often, patients should tell their doctors to evaluate how whether the drug is properly controlling blood sugar levels. Janumet contains a combination of the widely used metformin and sitagliptin, a medication available as a single ingredient in the brand name drug Januvia. Both Janumet and Januvia are known as dipeptidyl peptidase-4 (DPP-4) inhibitors and are in a relatively new class of medications known as incretin ... Read More

FDA opens investigation into heart failure risk with diabetes drugs Onglyza, Kombiglyze

The Food and Drug Administration (FDA) has opened an investigation into the safety of the type 2 diabetes drug saxagliptin after a recent study published in the New England Journal of Medicine (NEJM), reported an increased rate of hospitalizations for heart failure in patients taking the drug. Heart failure occurs when the heart does not efficiently pump blood throughout the body. It can lead to more serious and life threatening problems. Saxagliptin is sold in the United States under the brand names Onglyza and Kombiglyze XR. Patients currently taking saxagliptin should talk with their health care providers about any questions ... Read More

European diabetes summit focuses on pancreatic cancer, heart attack risks with Byetta, Januvia

A major focus of the recent meeting of the European Association for the Study of Diabetes focused on the risks and benefits of so-called incretin mimetics, a class of type 2 diabetes drugs that include glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. The diabetes experts zeroed in on whether the drug increased the risk for cardiovascular events or pancreatic disease including acute pancreatitis and pancreatic cancer. The concerns were timely. GLP-1 and DPP-4 drugs are relatively new treatments for Type 2 diabetes. In 2005, Byetta became the first GLP-1 drug to be approved by the FDA. A year ... Read More

Type 2 diabetes drug Victoza may improve vascular health but poses cancer risk

Victoza, a type 2 diabetes treatment that works to regulate glucose, may improve the condition of arteries and possibly protect against heart attack or stroke, a new report shows. However, that benefit will have to be weighed against the drug’s cancer risks. Victoza, also known as liragliutide, is an injection made by Novo Nordisk to treat high blood sugar in type 2 diabetics. Many people may be familiar with the drug’s former spokesperson, celebrity chef Paula Deen, who after accepting the company’s offer to front their drug, admitted she was diagnosed with type 2 diabetes two years prior. She has ... Read More

Type 2 diabetes drug does not reduce risk of heart attack, stroke, death

Diabetes drug Onglyza (saxagliptin) does not reduce the risk of heart attacks, strokes or death from cardiovascular causes compared to a placebo, drug makers Bristol Myers Squibb and AstraZeneca said. The companies had conducted clinical trials to determine if the Type 2 diabetes treatment could help reduce the risk of non-fatal heart attacks and ischemic strokes and death from cardiovascular problems as well as lower blood glucose levels. Onglyza did not perform better than a placebo; however, it was not inferior to the placebo either. The clinical trials involved 16,500 people with diabetes as well as a history of heart ... Read More